XML 20 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document and Entity Information - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Mar. 19, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Trading Symbol TSHA    
Entity Registrant Name Taysha Gene Therapies, Inc.    
Entity Central Index Key 0001806310    
Current Fiscal Year End Date --12-31    
Entity Current Reporting Status Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity File Number 001-39536    
Entity Tax Identification Number 84-3199512    
Entity Address, Address Line One 3000 Pegasus Park Dr    
Entity Address Address Line2 Ste 1430    
Entity Address, City or Town Dallas    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 75247    
City Area Code 214    
Local Phone Number 612-0000    
Entity Common Stock, Shares Outstanding   287,269,885  
Title of 12(b) Security Common stock, par value $0.00001 per share    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code DE    
Entity Interactive Data Current Yes    
Document Annual Report true    
Document Transition Report false    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Public Float     $ 544.8
Auditor Name Deloitte & Touche LLP    
Auditor Location Chicago, IL    
Auditor Firm ID 34    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Taysha Gene Therapies, Inc. and subsidiaries (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

    
Documents Incorporated by Reference

Portions of the registrant’s definitive Proxy Statement relating to the 2026 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the year ended December 31, 2025.